Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Quantitative measurement of alterations in DNA damage repair (DDR) pathways using single cell network profiling (SCNP).

Rosen DB, Leung LY, Louie B, Cordeiro JA, Conroy A, Shapira I, Fields SZ, Cesano A, Hawtin RE.

J Transl Med. 2014 Jun 25;12:184. doi: 10.1186/1479-5876-12-184.

2.

Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II.

Hawtin RE, Stockett DE, Byl JA, McDowell RS, Nguyen T, Arkin MR, Conroy A, Yang W, Osheroff N, Fox JA.

PLoS One. 2010 Apr 15;5(4):e10186. doi: 10.1371/journal.pone.0010186.

3.

The economic burden to the public health system of treating non-viral injecting-related injury and disease in Australia (a cost of illness analysis).

Sweeney R, Conroy AB, Dwyer R, Aitken CK.

Aust N Z J Public Health. 2009 Aug;33(4):352-7. doi: 10.1111/j.1753-6405.2009.00407.x.

PMID:
19689596
4.

SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples.

Conroy A, Stockett DE, Walker D, Arkin MR, Hoch U, Fox JA, Hawtin RE.

Cancer Chemother Pharmacol. 2009 Sep;64(4):723-32. doi: 10.1007/s00280-008-0921-5. Epub 2009 Jan 24.

PMID:
19169685
5.

Prevalence and predictors of injecting-related injury and disease among clients of Australia's needle and syringe programs.

Topp L, Iversen J, Conroy A, Salmon AM, Maher L; Collaboration of Australian NSPs.

Aust N Z J Public Health. 2008 Feb;32(1):34-7. doi: 10.1111/j.1753-6405.2008.00163.x.

PMID:
18290911
6.

A novel zinc finger transcription factor with two isoforms that are differentially repressed by estrogen receptor-alpha.

Conroy AT, Sharma M, Holtz AE, Wu C, Sun Z, Weigel RJ.

J Biol Chem. 2002 Mar 15;277(11):9326-34. Epub 2002 Jan 4.

Supplemental Content

Loading ...
Support Center